Recruiting
Renal transplant
RecruitingSafety of Two Doses of Siplizumab Compared with Rabbit Anti‑Human Thymocyte Immunoglobulin in Kidney Transplant Recipients Receiving Standard Immunosuppression
Registered drug
Safety of Two Doses of Siplizumab Compared with Rabbit Anti‑Human Thymocyte Immunoglobulin in Kidney Transplant Recipients Receiving Standard Immunosuppression
Registered drug
- Disease:Renal transplant
- Substances:SiplizumabRabbit Anti-Human Thymocyte Immunoglobulin
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Siplizumab
- Sponsor:Itb-Med LLC




